Cortigent, Inc. (CRGT)

Cortigent will go public soon, but the exact IPO date is still unknown.
IPO Price
Shares Offered
Deal Size
Chart not available yet
Data will show when the stock starts trading.
Market Cap 65.00M
Revenue (ttm) n/a
Net Income (ttm) -8.60M
Shares Out 6.50M
EPS (ttm) -1.32
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Open n/a
Previous Close n/a
Day's Range n/a
52-Week Range n/a
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About CRGT

Cortigent, through its predecessor Second Sight Medical Products, Inc., is a pioneer in developing targeted neurostimulation systems to help patients recover critical body functions. Our technology combines advanced neuroscience with proprietary microelectronics, software, and data processing capabilities to provide artificial vision and potentially restore muscle movement. Our first commercial system, “Argus II,” was approved by the U.S. Food & Drug Administration under a Humanitarian Device Exemption and has provided artificial vision to hund... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 2022
Employees 13
Stock Exchange NASDAQ
Ticker Symbol CRGT
Full Company Profile

Financial Performance

Financial Statements


Vivani Medical Announces Public Filing of Registration Statement for the Proposed Initial Public Offering of Cortigent, Inc., a Subsidiary Advancing the Business of its Neuromodulation Division

Vivani Medical, Inc. (NASDAQ: VANI), an innovative, clinical-stage biopharmaceutical company that develops novel, long-term therapeutic implants, today announced the filing of a Registration Statement...

1 year ago - Business Wire

Visual prosthetics developer Cortigent files for a $17 million IPO

Cortigent, a visual prosthetics developer being spun out of Vivani Medical, filed on Monday with the SEC to raise up to $17 million in an initial public offering.

1 year ago - Renaissance Capital

Cortigent IPO Registration Document (S-1)

Cortigent has filed to go public with an IPO on the NASDAQ.

1 year ago - SEC